S. 440 · 116th Congress
PACED Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
2 cosponsors · 2 R
2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Preserving Access to Cost Effective Drugs Act or the PACED Act
What it does: CRS summary · Reported to Senate · Jun 28, 2019
Preserving Access to Cost Effective Drugs Act or the PACED Act
This bill prohibits patent owners from asserting tribal sovereign immunity as a defense in certain proceedings before the U.S. Patent and Trademark Office, including patent validity challenge proceedings before the Patent Trial and Appeal Board (PTAB). The prohibition also applies to court actions and proceedings before the International Trade Commission.
Sovereign immunity for foreign states shall apply in the PTAB as it applies in federal court. The abrogation of sovereign immunity shall not apply to states or institutions of higher education (i.e., public state universities and institutions).
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: PACED Act
Also known as: Preserving Access to Cost Effective Drugs Act
Latest action (Jun 28, 2019): Placed on Senate Legislative Calendar under General Orders. Calendar No. 129.
Policy area: Commerce · Origin: Senate · Introduced: Feb 12, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.